Search bioRxivSearch

bioRxiv · 10.1101/101790

Transmission Bottleneck Size Estimation from Pathogen Deep-Sequencing Data, with an Application to Human Influenza A Virus

Abstract

The bottleneck governing infectious disease transmission describes the size of the pathogen population transferred from a donor to a recipient host. Accurate quantification of the bottleneck size is of particular importance for rapidly evolving pathogens such as influenza virus, as narrow bottlenecks would limit the extent of transferred viral genetic diversity and, thus, have the potential to slow the rate of viral adaptation. Previous studies have estimated the transmission bottleneck size governing viral transmission through statistical analyses of variants identified in pathogen sequencing data. The methods used by these studies, however, did not account for variant calling thresholds and stochastic dynamics of the viral population within recipient hosts. Because these factors can skew bottleneck size estimates, we here introduce a new method for inferring transmission bottleneck sizes that explicitly takes these factors into account. We compare our method, based on beta-binomial sampling, with existing methods in the literature for their ability to recover the transmission bottleneck size of a simulated dataset. This comparison demonstrates that the beta-binomial sampling method is best able to accurately infer the simulated bottleneck size. We then apply our method to a recently published dataset of influenza A H1N1p and H3N2 infections, for which viral deep sequencing data from inferred donor-recipient transmission pairs are available. Our results indicate that transmission bottleneck sizes across transmission pairs are variable, yet that there is no significant difference in the overall bottleneck sizes inferred for H1N1p and H3N2. The mean bottleneck size for influenza virus in this study, considering all transmission pairs, was Nb = 196 (95% confidence interval 66-392) virions. While this estimate is consistent with previous bottleneck size estimates for this dataset, it is considerably higher than the bottleneck sizes estimated for influenza from other datasets.\n\nAuthor SummaryThe transmission bottleneck size describes the size of the pathogen population transferred from the donor to recipient host at the onset of infection and is a key factor in determining the rate at which a pathogen can adapt within a host population. Recent advances in sequencing technology have enabled the bottleneck size to be estimated from pathogen sequence data, though there is not yet a consensus on the statistical method to use. In this study, we introduce a new approach for inferring the transmission bottleneck size from sequencing data that accounts for the criteria used to identify sequence variants and stochasticity in pathogen replication dynamics. We show that the failure to account for these factors may lead to underestimation of the transmission bottleneck size. We apply this method to a previous dataset of human influenza A infections, showing that transmission is governed by a loose transmission bottleneck and that the bottleneck size is highly variable across transmission events. This work advances our understanding of the bottleneck size governing influenza infection and introduces a method for estimating the bottleneck size that can be applied to other rapidly evolving RNA viruses, such as norovirus and RSV.

Source connections

Explore related subjects

Keep this discovery

BibTeXRIS

Sobel Leonard, A., Weissman, D., Greenbaum, B., Ghedin, E., Koelle, K.. 2017-01-19. Transmission Bottleneck Size Estimation from Pathogen Deep-Sequencing Data, with an Application to Human Influenza A Virus. https://doi.org/10.1101/101790

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A conserved cysteine-histidine-glutamate metal site identifies DUF501 (Rv1025), an essential uncharacterised protein family of Mycobacterium tuberculosis, as a candidate metalloenzyme and drug target

A substantial fraction of the Mycobacterium tuberculosis proteome remains functionally uncharacterised. Rv1025, a 155-residue protein carrying the domain of unknown function DUF501 (Pfam PF04417), is essential by transposon mutagenesis and vulnerable by CRISPR interference, an attractive but neglected drug target, yet has never been functionally described. The family (4,370 proteins, no Gene Ontology term, no solved structure) is uncharacterised across all organisms and essential in three Actinobacterial genera. A Foldseek search of the AlphaFold model against complete structural databases finds no significant homolog, indicating a novel fold. The operon eno-divIC-Rv1025-ppx2 is conserved across the Actinobacteria phylum, yet AlphaFold-Multimer finds no direct complex between Rv1025 and its neighbour DivIC. Instead, conservation across 8,700 homologous sequences reveals a near-invariant Cys113-His115-Glu59 cluster forming a pocket. Holo AlphaFold3 predictions with Zn, Fe and Mn confidently place a divalent metal on this triad at 2.25-2.47 A; mutating the triad relocates the metal, and an independent backbone-geometry predictor recovers the same site, confirming specificity. The triad is universal across the family: present in all 1,472 near-complete bacterial sequences of the Pfam alignment, with no non-conservative substitution among the 2,228 sequences examined, a defining feature of bacterial DUF501 rather than a mycobacterial peculiarity. We propose that DUF501 is a metal-binding protein and candidate metalloenzyme, the first functional hypothesis for this family, whose conserved, essential metal pocket is a promising drug target. As the predictions build on a conservation-defined site within a fully computational study, they are supportive rather than proof of metal occupancy and warrant experimental validation.

microbiology

Mycoplasmal endosymbionts of Trichomonas vaginalis are associated with reduced risk for Chlamydia trachomatis endometrial infection in asymptomatic, coinfected, women.

Trichomonas vaginalis is a protozoan parasite that causes trichomoniasis, the most common curable non-viral sexually transmitted infection, and Chlamydia trachomatis is a bacterial pathogen that can ascend to the upper genital tract and cause pelvic inflammatory disease, infertility, and ectopic pregnancy. T. vaginalis harbors bacterial endosymbionts, including Candidatus Malacoplasma girerdii, an obligate symbiont, and Metamycoplasma hominis, which can live freely or symbiotically. In a 16S rRNA sequencing study of the cervicovaginal microbiome of women at high risk for chlamydial infection, Ca. M. girerdii abundance was one of 13 features predicting lack of chlamydial spread to the endometrium, despite no direct association between T. vaginalis infection and reduced chlamydial ascension. Investigating the relationship between these microorganisms further, we found that T. vaginalis vaginal abundance correlated positively with chlamydial burden in women whose infection was confined to the cervix, while a nonsignificant inverse relationship was seen in women with endometrial spread. Among participants with high chlamydial burden, Ca. M. girerdii was detected exclusively in women without endometrial infection. Both endosymbionts trended toward more frequent detection, and higher abundance, in coinfected women without endometrial spread, while M. hominis abundance correlated strongly with T. vaginalis burden in this group. These findings suggest that mycoplasmal endosymbionts of T. vaginalis, rather than T. vaginalis itself, are microbial factors limiting chlamydial ascension, and point to a three-way interaction between parasite, endosymbiont, and bacterial pathogen that shapes upper genital tract C. trachomatis infection risk.

microbiology

Understanding the physiological alterations of Vibrio cholerae upon exposure to L-ascorbic acid

The scourge of cholera remains a major global public health threat. It affects up to 4 million people worldwide and causes tens of thousands of deaths each year. The disease is experiencing a concerning resurgence in many parts of Africa, the Middle East, and Asia. To effectively tackle cholera and circumvent rising antimicrobial resistance, targeted biological and preventive approaches, complementing traditional rehydration, are urgently needed. In this regard, our group has demonstrated the efficacy of L-ascorbic acid in controlling the growth and pathogenesis of Vibrio cholerae in vitro. The present work further provides a mechanistic elucidation of the L-ascorbic acid-mediated physiological changes in V. cholerae and also bolsters such a non-antibiotic approach to control cholera.

microbiology